Abstract

This review scrutinizes the intricate landscape of drug-drug interactions in the management of coexisting sickle cell anemia and diabetes, two chronic conditions that often intersect, challenging healthcare providers in their pursuit of optimal patient care. Sickle cell anemia, a hereditary hemoglobinopathy, and diabetes, a metabolic disorder, present a complex interplay that requires careful consideration of treatment strategies and potential interactions between medications prescribed for both conditions. This abstract encapsulates the essence of the review, emphasizing the need for a thorough understanding of drug interactions to ensure effective management and improved outcomes in individuals navigating the challenging intersection of sickle cell anemia and diabetes